Last reviewed · How we verify
Propranolol, Norfloxacin, VSL#3
This is a combination therapy using propranolol (beta-blocker), norfloxacin (fluoroquinolone antibiotic), and VSL#3 (probiotic) to manage portal hypertension and associated complications through hemodynamic reduction, bacterial overgrowth suppression, and gut microbiota restoration.
This is a combination therapy using propranolol (beta-blocker), norfloxacin (fluoroquinolone antibiotic), and VSL#3 (probiotic) to manage portal hypertension and associated complications through hemodynamic reduction, bacterial overgrowth suppression, and gut microbiota restoration. Used for Portal hypertension and variceal bleeding prevention in cirrhosis, Hepatic encephalopathy prophylaxis in advanced liver disease.
At a glance
| Generic name | Propranolol, Norfloxacin, VSL#3 |
|---|---|
| Sponsor | Govind Ballabh Pant Hospital |
| Drug class | Combination therapy (beta-blocker + fluoroquinolone antibiotic + probiotic) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Hepatology |
| Phase | Phase 3 |
Mechanism of action
Propranolol reduces portal pressure and variceal bleeding risk via non-selective beta-blockade. Norfloxacin provides selective intestinal decontamination to reduce pathogenic gram-negative bacteria that contribute to bacterial translocation and hepatic encephalopathy. VSL#3 restores beneficial commensal bacteria to improve intestinal barrier function and reduce endotoxemia in cirrhotic patients.
Approved indications
- Portal hypertension and variceal bleeding prevention in cirrhosis
- Hepatic encephalopathy prophylaxis in advanced liver disease
Common side effects
- Fatigue / asthenia
- Diarrhea
- Hypotension
- Bradycardia
- Gastrointestinal disturbance
Key clinical trials
- Probiotics for Portal Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Propranolol, Norfloxacin, VSL#3 CI brief — competitive landscape report
- Propranolol, Norfloxacin, VSL#3 updates RSS · CI watch RSS
- Govind Ballabh Pant Hospital portfolio CI